ACROSS T2D is the Global Academy for Cardiovascular Risks, Outcomes and Safety Studies in Type 2 Diabetes.
The ACROSS T2D programme has been established as a collaboration between leading international experts to share their knowledge and best clinical practice with colleagues who manage patients with type 2 diabetes (T2D).
The slides in the educational modules of the ACROSS T2D website provide a holistic overview of the pathophysiology of cardiovascular (CV) comorbidities associated with T2D. In addition, the slides provide details of past, current and planned CV outcomes trials (CVOTs), including study objectives and design, as well as efficacy and safety results as these become available.
The ACROSS T2D programme represents our vision of a multidisciplinary and collaborative approach to the management of T2D.
Our effort was triggered by evidence that, despite advances in treatment, CV disease remains the primary cause of death in patients with T2D: over half of all patients with T2D die of CV disease worldwide. The healthcare community is therefore faced with the urgent need to bring discussions around early CV risk management to the forefront with disseminating balanced and scientifically robust evidence.
CVOTs are conducted to determine the CV benefit–risk profile of recently approved glucose-lowering therapies. Differences in design, patient populations and comparators among these trials call for educational programmes so that physicians worldwide can better evaluate the clinical relevance of these trials.